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Smoking and NASH: A hidden message from the GREACE trial
Forty six out of 437 patients (10.3%) with abnormal liver tests
were current smokers, as compared to 51/1163 with normal liver
tests (4.4%). In addition, 146/437 (33.4%) with abnormal liver
tests were past smokers as compared to 290/1163 (24.9%) with
normal liver tests.
Using this data, we were able to calculate the odds-ratio (OR)
that a current smoker has abnormal liver tests compared to a life-
time non-smoker to be 3.03 (95% conﬁdence interval 1.98–4.6).
Similarly, the odds-ratio for a past smoker having abnormal liver
tests compared to a lifetime non-smoker is 1.69 (95% conﬁdence
interval 1.32–2.16) and a patient with any history of smoking
developing abnormal liver test is 1.88 (95% conﬁdence interval
1.51–2.37). These data show a higher risk for current smokers
to have abnormal liver tests as compared to past smokers.
The GREACE trial lacked liver biopsies to conﬁrm a diagnosis
of NAFLD, and relied on abnormal liver tests and abdominal ultra-
sound to make a diagnosis of presumed NAFLD. However, the
Letters to the EditorTo the Editor:
The article by Zein et al. in the April issue of this Journal adds to a
growing body of evidence that tobacco use may be linked to pro-
gression of non-alcoholic fatty liver disease (NAFLD) [1]. How-
ever, while there was an association between the degree of
ﬁbrosis and tobacco use among the 1091 patients studied, the
authors mention that they could not, surprisingly, ﬁnd an associ-
ation between NASH and current tobacco use. Another recent
trial may provide some data regarding this.
Athryos and colleagues recently used a post-hoc analysis of
the GREACE trial to demonstrate that statins were safe for use
in patients with elevated liver enzymes and presumed NAFLD
[2]. However, the authors of that trial seem to have overlooked
data that suggest an association between smoking and presumed
NAFLD. A review of the baseline characteristics in the GREACE
trial shows a large difference in the number of current and past
smokers between patients with normal and abnormal liver tests.300 Journal of Hepatology 2012 vol. 56 j 298–302
authors had carefully excluded other causes of liver disease. The
fact that about 90% of those with abnormal liver tests had co-
existent metabolic syndrome lends further support to the
presumption that the patients studied likely had NAFLD.
As compared to the NASH CRN study, the GREACE study
included a larger number of overall patients (1091 vs. 1600),
although there were less NASH patients (1091 vs. 437). More
importantly, the GREACE trial had a comparator group with
normal liver tests, which was lacking in the NASH CRN study.
This may have been the reason why the GREACE trial was able
to pick up a difference, although the percentages of current
smokers were similar in the two trials (9.5% in NASH CRN vs.
10.3% in the GREACE trial). The fact that we compared current
smokers to lifetime non-smokers also likely increased the odds-
ratio, and similar analysis of the NASH CRN data may yield com-
parable results.
Thus, there appears to be strong current evidence to support a
role for smoking in the development and progression of NAFLD.
We agree with Zein et al. that smoking cessation should be rec-
ommended to those patients suspected to have NAFLD.
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Reply to: ‘‘Smoking and NASH: A hidden message
from the GREACE trial’’
To the Editor:
We appreciate the interest shown in our work by Drs. Babu and
Paul. In their Letter to the Editor, they comment on a higher fre-
quency of smoking reported by Athyros et al. among patients in
the GREACE trial with presumed NAFLD compared to patients
with normal liver tests [1]. Interestingly, a previous study by
Suzuki et al. also reported an association between current smok-
ing and increase in serum ALT in subjects with presumed NAFLD
[2]. Drs. Babu and Paul point out that, ﬁtting with our earlier
report [3], a history of smoking was more frequent among sub-
jects in the GREACE trial with presumed NAFLD compared to
those with normal liver tests, and that in addition, current smok-
ing was more frequent among subjects with presumed NAFLD
compared to subjects with normal liver tests. These are interest-
ing observations, and we agree with Drs. Babu and Paul that the
available experimental and clinical evidence to date supports that
smoking aggravates liver injury in NAFLD.
However, although our conclusions and those of their analysis
of the GREACE data undoubtedly point in the same direction,
there are important differences between the observations of
Drs. Babu and Paul and our original study. The report by Athyros
et al. is based on a post hoc analysis of the GREACE trial data look-
ing at the impact of treatment with statins on cardiovascular
events in patients with mild to moderately elevated liver tests.
The ﬁrst important difference between the studies is that, as cor-
rectly stated by Drs. Babu and Paul in their letter, the GREACE
trial used liver enzymes and ultrasound results as suggestive cri-
teria for NAFLD diagnosis but lacked histopathological diagnosis
conﬁrmation and characterization. In contrast, the diagnosis of
NAFLD in our cohort was well documented and characterized
by histology.
The second important difference is that our study aimed at
investigating the association between smoking and severity of
liver ﬁbrosis in NAFLD in a cohort of NAFLD patients. In contrast,
Drs. Babu and Paul looked at the frequency of smoking history
and current smoking in patients in the GREACE trial with pre-
sumed NAFLD compared to those without NAFLD. These are fun-
damentally different comparisons.
In conclusion, we agree with Drs. Babu and Paul and value
their contribution to this important discussion. We support their
opinion that smoking cessation should be recommended in
patients with NAFLD. Future studies with careful prospective data
collection on smoking and other predictors of disease severity in
biopsy conﬁrmed NAFLD are warranted.
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